Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
10 avr. 2024 08h00 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new...
ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
02 avr. 2024 09h05 HE
|
ADARx Pharmaceuticals
ADARx Pharmaceuticals, next-generation RNA therapeutics developer, appoints Dr. Chris Storgard as Chief Medical Officer
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease
18 mars 2024 03h00 HE
|
Senisca Ltd
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease £3.7 million seed financing supported by consortium of new and...
RNA Therapeutics Market is Expected to Reach $18.0 billion | MarketsandMarkets.
02 oct. 2023 08h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The RNA therapeutics industry is poised for a transformative future as groundbreaking research and technological advancements continue to accelerate the...
SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer
13 juil. 2023 04h00 HE
|
SiSaf Ltd
GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I....
FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis
15 mai 2023 03h00 HE
|
SiSaf Ltd
GUILDFORD, England, May 15, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA delivery and therapeutics company, announces that SIS-101-ADO, its siRNA therapeutic for patients with Autosomal Dominant...
SiSaf Appoints Dr. Richard Goodfellow to Board of Directors
05 avr. 2023 03h00 HE
|
SiSaf Ltd
GUILDFORD, England, April 05, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announced that it has appointed Dr. Richard Goodfellow to its Board of Directors. ...
SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer
02 mars 2023 04h00 HE
|
SiSaf Ltd
GUILDFORD, United Kingdom, March 02, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announces its collaboration with the University of Leipzig, Germany, to develop...
The RNA targeting small molecule therapies market is projected to be worth around USD 8.3 billion in 2030, growing at an annualized rate of 35.26% during the period 2021-2030, claims Roots Analysis
23 mars 2022 12h55 HE
|
Roots Analysis
London, March 23, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “RNA Targeting Small Molecules Therapeutics Market, 2021-2030” report to its list of offerings. RNAs...
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
06 juil. 2021 09h00 HE
|
Auris Medical AG
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission...